Auteurs
Curation
PubMed
Racine
Curation
Checkpoint
PubMed
Racine
PubMed
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Curation (PubMed)

Index « Auteurs » - entrée « Keita Fujikawa »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Keisuke Tanaka < Keita Fujikawa < Keith A. Betts  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 12.
Ident.Authors (with country if any)Title
000228 (2019) Tomohisa Uchida ; Momoko Okamoto ; Keita Fujikawa ; Daisuke Yoshikawa ; Akinari Mizokami ; Tomo Mihara ; Akira Kondo ; Kazuo Ohba ; Kazuhiro Kurohama ; Masahiro Nakashima ; Ichiro Sekine ; Shigeki Nakamura [Japon] ; Yoshitsugu Miyazaki [Japon] ; Atsushi Kawakami [Japon]Gastric mucormycosis complicated by a gastropleural fistula: A case report and review of the literature.
000339 (2019) Ryuki Sakaguchi [Japon] ; Keita Fujikawa [Japon] ; Momoko Okamoto [Japon] ; Emi Matsuo [Japon] ; Kohei Matsumoto [Japon] ; Tomohisa Uchida [Japon] ; Kawashiri Shin-Ya [Japon] ; Masahiro Nakashima [Japon] ; Akinari Mizokami [Japon] ; Atsushi Kawakami [Japon]Rheumatoid Arthritis Complicated with Nasal Septum Perforation Due to Methotrexate-associated Lymphoproliferative Disorder.
000534 (2018) Masataka Umeda [Japon] ; Tomohiro Koga [Japon] ; Kunihiro Ichinose [Japon] ; Ayuko Takatani [Japon] ; Takashi Igawa [Japon] ; Toshimasa Shimizu [Japon] ; Shoichi Fukui [Japon] ; Ayako Nishino [Japon] ; Yoshiro Horai [Japon] ; Yasuko Hirai [Japon] ; Shin-Ya Kawashiri [Japon] ; Naoki Iwamoto [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Tomoki Origuchi [Japon] ; Toshiyuki Aramaki [Japon] ; Yukitaka Ueki [Japon] ; Akitomo Okada [Japon] ; Keita Fujikawa [Japon] ; Naoki Matsuoka [Japon] ; Atsushi Kawakami [Japon]Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice.
000E05 (????) Shin-Ya Kawashiri [Japon] ; Ayako Nishino [Japon] ; Takahisa Suzuki [Japon] ; Yoshikazu Nakashima [Japon] ; Yoshiro Horai [Japon] ; Yukitaka Ueki [Japon] ; Toshiyuki Aramaki [Japon] ; Keita Fujikawa [Japon] ; Munetoshi Nakashima [Japon] ; Akitomo Okada [Japon] ; Kiyoshi Migita [Japon] ; Akinari Mizokami [Japon] ; Naoki Matsuoka [Japon] ; Masanobu Mine [Japon] ; Soko Sakito [Japon] ; Naoki Iwamoto [Japon] ; Kunihiro Ichinose [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Tomoki Origuchi [Japon] ; Kiyoshi Aoyagi [Japon] ; Katsumi Eguchi [Japon] ; Atsushi Kawakami [Japon]Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
000F90 (2016) Naoki Iwamoto [Japon] ; Shoichi Fukui [Japon] ; Masataka Umeda [Japon] ; Ayako Nishino [Japon] ; Yoshikazu Nakashima [Japon] ; Takahisa Suzuki [Japon] ; Yoshiro Horai [Japon] ; Fumiaki Nonaka [Japon] ; Akitomo Okada [Japon] ; Tomohiro Koga [Japon] ; Shin-Ya Kawashiri [Japon] ; Keita Fujikawa [Japon] ; Toshiyuki Aramaki ; Kunihiro Ichinose [Japon] ; Yasuko Hirai [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Kaoru Terada ; Munetoshi Nakashima [Japon] ; Akinari Mizokami [Japon] ; Tomoki Origuchi [Japon] ; Katsumi Eguchi [Japon] ; Yukitaka Ueki ; Atsushi Kawakami [Japon]Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
001034 (2017) Masataka Umeda [Japon] ; Toshiyuki Aramaki [Japon] ; Keita Fujikawa [Japon] ; Naoki Iwamoto [Japon] ; Kunihiro Ichinose [Japon] ; Kaoru Terada [Japon] ; Gou Takeo [Japon] ; Nobuhisa Yonemitsu [Japon] ; Yukitaka Ueki [Japon] ; Kiyoshi Migita [Japon] ; Atsushi Kawakami [Japon]Tocilizumab is effective in a familial Mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis.
001565 (????) Keita Fujikawa [Japon] ; Kiyoshi Migita ; Toshiaki Tsukada ; Masataka Umeda ; Fumiaki Nonaka ; Atsushi Kawakami ; Katsumi EguchiInterleukin-6 targeting therapy in familial Mediterranean fever.
001A85 (2011) Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami ; Naoki Iwamoto ; Keita Fujikawa ; Toshiyuki Aramaki ; Mami Tamai ; Satoshi Yamasaki ; Hideki Nakamura ; Tomoki Origuchi ; Yukitaka Ueki ; Kiyoshi Migita ; Akinari Mizokami ; Kiyoshi Aoyagi ; Katsumi EguchiIn rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.
001A91 (2011) Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami ; Naoki Iwamoto ; Keita Fujikawa ; Toshiyuki Aramaki ; Mami Tamai ; Satoshi Yamasaki ; Hideki Nakamura ; Yukitaka Ueki ; Kiyoshi Migita ; Akinari Mizokami ; Tomoki Origuchi ; Kiyoshi Aoyagi ; Katsumi EguchiDisease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
001C22 (2011) Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami ; Satoshi Yamasaki ; Takahiro Imazato ; Naoki Iwamoto ; Keita Fujikawa ; Toshiyuki Aramaki ; Mami Tamai ; Hideki Nakamura ; Hiroaki Ida ; Tomoki Origuchi ; Yukitaka Ueki ; Katsumi EguchiEffects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis.
001C33 (2010) Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami ; Naoki Iwamoto ; Keita Fujikawa ; Toshiyuki Aramaki ; Mami Tamai ; Kazuhiko Arima ; Kunihiro Ichinose ; Makoto Kamachi ; Satoshi Yamasaki ; Hideki Nakamura ; Tomoki Origuchi ; Hiroaki Ida ; Katsumi EguchiSwitching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
001C35 (2009) Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami ; Naoki Iwamoto ; Keita Fujikawa ; Toshiyuki Aramaki ; Mami Tamai ; Kazuhiko Arima ; Makoto Kamachi ; Satoshi Yamasaki ; Hideki Nakamura ; Toshiyuki Tsurumoto ; Masafumi Kono ; Hiroyuki Shindo ; Hiroaki Ida ; Tomoki Origuchi ; Katsumi EguchiProinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/Author.i -k "Keita Fujikawa" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/Author.i  \
                -Sk "Keita Fujikawa" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Curation
   |type=    indexItem
   |index=    Author.i
   |clé=    Keita Fujikawa
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021